Developing a microRNA screening fingerprint for breast cancer


Intranasal Oxytocin Use in Identifying the Micro-RNA Fingerprint in NAF, Serum, and Tissue in Patients with DCIS or Invasive Breast Cancer

This study aims to determine the feasibility of assessing microRNA profiles in nipple aspirate fluid (NAF), serum, and tissue of women diagnosed with DCIS or invasive breast cancer. Because 90% of breast cancers originate from ductal epithelium, it is possible that cells and secretions collected from such ducts would allow for earlier detection of breast cancer. Ideally, NAF may be used to identify biomarkers that predict the risk of breast cancer and/or detect breast cancer in its early stages.

Are you Eligible? (Inclusion Criteria)

Patients with DCIS or invasive breast cancer scheduled for breast surgery at NYP/Columbia

Specialty Area(s)

Trial Location

Columbia University Medical Center
Department of Surgery
New York, NY 10032
United States